OBJECTIVE: To evaluate the role of cardiac troponin T (cTnT) in predicting death, recurrent ischemic events, and heart failure among community-dwelling persons with first myocardial infarction (MI). PATIENTS AND METHODS: Consecutive Olmsted County, Minnesota, residents with an incident MI between November 6, 2002, and December 31, 2007, were studied (N=1177; mean age, 68 years). Maximal cTnT value was measured at a median of 1 day after MI (median, 0.52 ng/mL; interquartile range, 0.16-1.75 ng/mL) and evaluated as a prognostic factor using measures of absolute risk. RESULTS: During a mean follow-up of 16 months, 276 deaths (23%) occurred, 341 patients (29%) experienced a recurrent ischemic event, and 326 patients (28%) experienced heart failure. A dose-response relationship was demonstrated early after MI between cTnT and the adjusted cumulative incidence of all outcomes. The multivariate-adjusted absolute risk differences (events per 100 patients) between the upper and lower cTnT tertiles at 30 days were 5.8 (95% confidence interval [CI], 1.4-10.2) for death, 5.2 (95% CI, 0.2-10.3) for recurrent ischemic event, and 6.9 (95% CI, 1.4-12.4) for heart failure. These differences were either maintained or increased at 2 years. CONCLUSION: In the community, cTnT level predicts death and nonfatal cardiac events independently of other prognostic factors. The increased risk associated with elevated cTnT level appears shortly after MI and persists for at least 2 years.
OBJECTIVE: To evaluate the role of cardiac troponin T (cTnT) in predicting death, recurrent ischemic events, and heart failure among community-dwelling persons with first myocardial infarction (MI). PATIENTS AND METHODS: Consecutive Olmsted County, Minnesota, residents with an incident MI between November 6, 2002, and December 31, 2007, were studied (N=1177; mean age, 68 years). Maximal cTnT value was measured at a median of 1 day after MI (median, 0.52 ng/mL; interquartile range, 0.16-1.75 ng/mL) and evaluated as a prognostic factor using measures of absolute risk. RESULTS: During a mean follow-up of 16 months, 276 deaths (23%) occurred, 341 patients (29%) experienced a recurrent ischemic event, and 326 patients (28%) experienced heart failure. A dose-response relationship was demonstrated early after MI between cTnT and the adjusted cumulative incidence of all outcomes. The multivariate-adjusted absolute risk differences (events per 100 patients) between the upper and lower cTnT tertiles at 30 days were 5.8 (95% confidence interval [CI], 1.4-10.2) for death, 5.2 (95% CI, 0.2-10.3) for recurrent ischemic event, and 6.9 (95% CI, 1.4-12.4) for heart failure. These differences were either maintained or increased at 2 years. CONCLUSION: In the community, cTnT level predicts death and nonfatal cardiac events independently of other prognostic factors. The increased risk associated with elevated cTnT level appears shortly after MI and persists for at least 2 years.
Authors: Russell V Luepker; Fred S Apple; Robert H Christenson; Richard S Crow; Stephen P Fortmann; David Goff; Robert J Goldberg; Mary M Hand; Allan S Jaffe; Desmond G Julian; Daniel Levy; Teri Manolio; Shanthi Mendis; George Mensah; Andrzej Pajak; Ronald J Prineas; K Srinath Reddy; Veronique L Roger; Wayne D Rosamond; Eyal Shahar; A Richey Sharrett; Paul Sorlie; Hugh Tunstall-Pedoe Journal: Circulation Date: 2003-11-10 Impact factor: 29.690
Authors: Jack V Tu; Donald J Willison; Frank L Silver; Jiming Fang; Janice A Richards; Andreas Laupacis; Moira K Kapral Journal: N Engl J Med Date: 2004-04-01 Impact factor: 91.245
Authors: Graham C Wong; David A Morrow; Sabina Murphy; Nicole Kraimer; Rupal Pai; David James; Debbie H Robertson; Laura A Demopoulos; Peter DiBattiste; Christopher P Cannon; C Michael Gibson Journal: Circulation Date: 2002-07-09 Impact factor: 29.690
Authors: Ronnier J Aviles; Arman T Askari; Bertil Lindahl; Lars Wallentin; Gang Jia; E Magnus Ohman; Kenneth W Mahaffey; L Kristin Newby; Robert M Califf; Maarten L Simoons; Eric J Topol; Peter Berger; Michael S Lauer Journal: N Engl J Med Date: 2002-06-27 Impact factor: 91.245
Authors: Yariv Gerber; Susan A Weston; Maurice Enriquez-Sarano; Sheila M Manemann; Alanna M Chamberlain; Ruoxiang Jiang; Véronique L Roger Journal: JAMA Cardiol Date: 2016-05-01 Impact factor: 14.676
Authors: Yariv Gerber; Susan A Weston; Cecilia Berardi; Sheila M McNallan; Ruoxiang Jiang; Margaret M Redfield; Véronique L Roger Journal: Am J Epidemiol Date: 2013-08-29 Impact factor: 4.897
Authors: William S Jenkins; Véronique L Roger; Allan S Jaffe; Susan A Weston; Omar F AbouEzzeddine; Ruoxiang Jiang; Sheila M Manemann; Maurice Enriquez-Sarano Journal: Am J Med Date: 2017-03-23 Impact factor: 4.965
Authors: Yejin Mok; Yingying Sang; Shoshana H Ballew; Ron C Hoogeveen; Christie M Ballantyne; Wayne Rosamond; Josef Coresh; Elizabeth Selvin; Kunihiro Matsushita Journal: Am Heart J Date: 2019-07-13 Impact factor: 4.749
Authors: Yariv Gerber; Susan A Weston; Maurice Enriquez-Sarano; Cecilia Berardi; Alanna M Chamberlain; Sheila M Manemann; Ruoxiang Jiang; Shannon M Dunlay; Véronique L Roger Journal: Circ Heart Fail Date: 2015-12-23 Impact factor: 8.790
Authors: Sheila M Manemann; Jennifer L St Sauver; Hongfang Liu; Nicholas B Larson; Sungrim Moon; Paul Y Takahashi; Janet E Olson; Walter A Rocca; Virginia M Miller; Terry M Therneau; Che G Ngufor; Veronique L Roger; Yiqing Zhao; Paul A Decker; Jill M Killian; Suzette J Bielinski Journal: BMJ Open Date: 2021-06-08 Impact factor: 3.006
Authors: Dominik Jenča; Vojtěch Melenovský; Josef Stehlik; Vladimír Staněk; Jiří Kettner; Josef Kautzner; Věra Adámková; Peter Wohlfahrt Journal: ESC Heart Fail Date: 2020-12-14